Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

008. Please dial 416-695-5800 or 800-408-3053 and enter code 3255778 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Prostate cancer patients ... receive less effective treatment and die sooner if they ... analyzed data from more than 41,200 American men who ... 2007. They followed them through 2009. Nearly 1,900 of ... two years before their prostate cancer was discovered. ...
(Date:7/11/2014)... Sacramento, CA (PRWEB) July 11, 2014 ... Luke Bryan Tickets at the Sleep Train Amphitheatre in ... few venues that can compare to what the Sleep Train ... countless musical events and special attractions over the course of ... October 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
(Date:7/11/2014)... The “Proteomics Market by Technology ... Surface Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents ... and studies the major market drivers, restraints, and ... Rest of the World (RoW). , The proteomics ... few years, mainly due to the increasing need ...
(Date:7/11/2014)... many years scientists have been trying to unravel mechanisms ... those cells that generate all blood cells including our ... is difficult because they can only be found in ... recapitulated in a culture dish. Now a group of ... Claudia Waskow (Technische Universitt Dresden) was able to generate ...
Breaking Medicine News(10 mins):Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Opening-up the stem cell niche 2
... from Allergy UK disclosed that food allergies are the reasons ... research was conducted among the British residents who have encountered ... end of this interesting survey, it was found out that ... health problems. ,Lactose intolerance is one of the ...
... University of Adelaide in the Discipline of Pharmacology have ... of heroin addicts around// the world. They have ... dosage levels for heroin addicts. ,The study ... effective in distributing drugs throughout their body to the ...
... study by Dr. David Goltzman, a professor of medicine and ... Periodontal Research at McGill University in Montreal//, and colleagues, have ... medicine and psychiatry. , Elderly persons aged above ... increased fractures. , The study published in the Archives ...
... Scientists at the University of Pennsylvania School of Medicine ... that could be "linked to the patient's thoughts, providing ... external stimuli." ,"We're at a junction now ... says senior author Douglas H. Smith, MD, Professor of ...
... at Rice University and pediatric specialists at Baylor College of ... buckyball nanoparticles as passkeys that allows drugs to enter cancer ... 21 issue of the journal Organic and Biomolecular Chemistry. ... outside world. Cell walls, or membranes, form a protective cocoon ...
... by researchers from the February issue of the American ... are more likely// to eat their offspring when they ... ,"The most drastic decision a father can make ... (Ph.D. candidate at Simon Fraser University), Lawrence Dill (Simon ...
Cached Medicine News:Health News:Genetic-Key to Stop Heroin Addicts 2Health News:Prozac-popping Elders at Higher Risk of Fractures 2Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the development and sale of patented ... generics and active pharmaceutical ingredients (API) announced that ... Macrolide Facility (JCM) has passed the internal quality ...
... NEW YORK, Nov. 9, 2011 ... research report is available in its ... and Reimbursement in Europe - Reference ... to Innovative Drugs Pose Significant Challenge ...
Cached Medicine Technology:JCM Passes Internal Quality Assessment for Azithromycin API Production 2JCM Passes Internal Quality Assessment for Azithromycin API Production 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 2Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 4Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 5Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 6Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... used in the ARED study, as well ... which suggested no AMD disease progression in ... period. Macula Complete also contains efficacious amounts ... support the mitochondria, as well as to ...
... MacularProtect delivers levels of ... vision and macular health in ... by The National Eye Institute. ... of lutein, an antioxidant found ...
... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
Medicine Products: